Abstract
Psychostimulant use increases anxious behavior, likely through interactions between central corticotropin-releasing factor (CRF) and serotonergic systems. The current study examined whether chronic amphetamine treatment (2.5mg/kg, 14 days) or withdrawal altered CRF receptor densities in the serotonergic dorsal raphe nucleus (dRN). Amphetamine treatment increased CRF(2) receptor densities in most subregions of the dRN, and CRF(2) receptors were still elevated following 6 weeks of withdrawal. No changes in CRF(1) receptor densities were observed following amphetamine treatment or during withdrawal. Selective increases in dRN CRF(2) receptors may be related to increased anxiety-like behaviors following psychostimulant use.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adrenal Cortex Hormones / metabolism
-
Amphetamine / pharmacology*
-
Amphetamine-Related Disorders / complications*
-
Amphetamine-Related Disorders / metabolism
-
Amphetamine-Related Disorders / psychology
-
Animals
-
Anxiety Disorders / chemically induced*
-
Anxiety Disorders / metabolism
-
Anxiety Disorders / physiopathology
-
Central Nervous System Stimulants / pharmacology
-
Corticotropin-Releasing Hormone / drug effects*
-
Corticotropin-Releasing Hormone / metabolism
-
Disease Models, Animal
-
Male
-
Mesencephalon / drug effects
-
Mesencephalon / metabolism
-
Raphe Nuclei / drug effects*
-
Raphe Nuclei / metabolism
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Corticotropin-Releasing Hormone / drug effects*
-
Receptors, Corticotropin-Releasing Hormone / metabolism
-
Stress, Psychological / chemically induced
-
Stress, Psychological / metabolism
-
Stress, Psychological / physiopathology
-
Up-Regulation / drug effects
-
Up-Regulation / physiology
Substances
-
Adrenal Cortex Hormones
-
CRF receptor type 2
-
Central Nervous System Stimulants
-
Receptors, Corticotropin-Releasing Hormone
-
Corticotropin-Releasing Hormone
-
Amphetamine